title: Molecular detection of codon 12 K-RAS mutations in circulating DNA from serum of colorectal cancer patients.
abstract: Point mutations of the K-RAS gene at codon 12 are found in about 40% of cases with colorectal cancer. The diagnostic implications of the detection of these mutations and their clinical utility are still unclear. The aim of this study was to test both the feasibility of the detection of the mutated K-RAS gene in serum and its potential role in colorectal cancer detection and monitoring. Codon 12 K-RAS mutations were examined in DNA extracted from the serum of 35 patients with colorectal cancer and were compared with the K-RAS status in the corresponding primary tumor. Molecular detection was performed by the mutant-enriched PCR (ME-PCR) assay, a sensitive method capable of distinguishing a small quantity of mutated DNA in the presence of abundant wild-type DNA. The occurrence of mutations was compared with clinicopathological parameters as well as CEA and CA19.9 serum levels. We found codon 12 K-RAS mutations in the tissue of 13/35 (37%) patients. Serum mutations were detected in 5/13 (38.5%) patients with mutated K-RAS in the tissue. 26/35 (74%) patients showed an identical K-RAS pattern in tissue and serum. No codon 12 K-RAS alterations were found in serum samples of 22 patients with benign gastrointestinal diseases. Elevated serum CEA levels were detected in 16 patients, four of whom also presented serum RAS mutations. Our results confirm that K-RAS mutations can be found in circulating DNA extracted from serum samples of patients with colorectal cancer and show that there is a correspondence between serum and tissue K-RAS patterns.
authors.affiliation: Center for Biological Markers of Malignancy, Regional Hospital ULSS 12, Venice, Italy. cnabo@provincia.venezia.it
authors.forename: C
authors.initials: C
authors.lastname: Salbe
authors.forename: C
authors.initials: C
authors.lastname: Trevisiol
authors.forename: E
authors.initials: E
authors.lastname: Ferruzzi
authors.forename: T
authors.initials: T
authors.lastname: Mancuso
authors.forename: R
authors.initials: R
authors.lastname: Nascimbeni
authors.forename: F
authors.initials: F
authors.lastname: Di Fabio
authors.forename: B
authors.initials: B
authors.lastname: Salerni
authors.forename: R
authors.initials: R
authors.lastname: Dittadi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018395:CA-19-9 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003062:Codon; D015179:Colorectal Neoplasms / Q000097:blood* / Q000401:mortality; D017931:DNA Primers / Q000737:chemistry; D004273:DNA, Neoplasm / Q000097:blood*; D011905:Genes, ras / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011446:Prospective Studies; D016283:Proto-Oncogene Proteins p21(ras) / Q000097:blood* / Q000235:genetics; D017422:Sequence Analysis, DNA
chemical_list: D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D003062:Codon; D017931:DNA Primers; D004273:DNA, Neoplasm; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)